Trial Profile
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Hydromethylthionine mesylate (Primary)
- Indications Dementia
- Focus Registrational; Therapeutic Use
- Sponsors TauRx Therapeutics
- 19 May 2020 According to a TauRx Pharmaceuticals media release, results are published in Journal of Alzheimer's Disease (https://doi.org/10.3233/JAD-191173)
- 19 May 2020 Results published in the Media Release
- 22 Jul 2016 According to a TauRx Pharmaceuticals media release, the results from this study will be presented at the 10th International Conference on Frontotemporal Dementias (ICFTD).